Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Director | December 04, 2020 | December 08, 2020 |
| GENERAL DYNAMICS CORPGD · Entity 2916 | Director · Chairman and CEO | July 31, 2026 | August 04, 2026 |
| JPMORGAN CHASE & COJPM · Entity 2795 | Director | September 30, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date December 04, 2020 · Filed December 08, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 41,004 |
Ending reported balance
After 2020-12-04 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2020-12-04 · Exercise / conversion · Acquired 3,333 · Balance 34,446 Row 2 · 2020-12-04 · Exercise / conversion · Acquired 11,348 · Balance 45,794 Row 3 · 2020-12-04 · Sale · Disposed 4,790 · Balance 41,004 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.275 to $107.285, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.84 · Expires 2022-04-26 | Direct | 0 |
Reported balance
After 2020-12-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-12-04 · Exercise / conversion · Disposed 3,333 · Balance 0 F2: Stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.48 · Expires 2023-04-25 | Direct | 0 |
Reported balance
After 2020-12-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-12-04 · Exercise / conversion · Disposed 11,348 · Balance 0 F2: Stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.275 to $107.285, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2: Stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
GENERAL DYNAMICS CORP
Report date July 31, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 766,457 |
Ending reported balance
After 2026-08-03 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-07-31 · Exercise / conversion · Acquired 166,660 · Balance 933,117 Row 2 · 2026-07-31 · Tax withholding · Disposed 115,092 · Balance 818,025 Row 3 · 2026-08-03 · Sale · Disposed 5,673 · Balance 812,352 F1: Sale prices ranged from $380.575 to $381.56. Reporting Person will provide, upon request by the Commission staff, General Dynamics, or a General Dynamics shareholder, full information regarding the number of shares sold at each separate sales price. Row 4 · 2026-08-03 · Sale · Disposed 22,707 · Balance 789,645 F2: Sale prices ranged from $381.575 to $382.56. Reporting Person will provide, upon request by the Commission staff, General Dynamics, or a General Dynamics shareholder, full information regarding the number of shares sold at each separate sales price. Row 5 · 2026-08-03 · Sale · Disposed 15,917 · Balance 773,728 F3: Sale prices ranged from $382.58 to $383.575. Reporting Person will provide, upon request by the Commission staff, General Dynamics, or a General Dynamics shareholder, full information regarding the number of shares sold at each separate sales price. Row 6 · 2026-08-03 · Sale · Disposed 7,271 · Balance 766,457 F4: Sale prices ranged from $383.62 to $384.07. Reporting Person will provide, upon request by the Commission staff, General Dynamics, or a General Dynamics shareholder, full information regarding the number of shares sold at each separate sales price. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $165.47 · Expires 2030-03-03 | Direct | 0 |
Reported balance
After 2026-07-31 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-07-31 · Exercise / conversion · Disposed 166,660 · Balance 0 F7: Fifty percent became exercisable on 03/04/2022, and the remaining fifty percent became exercisable on 03/04/2023. |
| Common StockSEC Table I · non-derivative | Indirect401(k) Plan | 5,926.943 |
Reported balance
Holding disclosure · report date 2026-07-31 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 5,926.943 F5: Includes share activity under General Dynamics 401(k) plan since date of Reporting Person's last ownership report. |
| Common StockSEC Table I · non-derivative | IndirectBy LLC | 30,000 |
Reported balance
Holding disclosure · report date 2026-07-31 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 30,000 F6: Represents shares held by a limited liability company for which the Reporting Person serves as a manager and the members of which are trusts for the benefit of the Reporting Person's children. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale prices ranged from $380.575 to $381.56. Reporting Person will provide, upon request by the Commission staff, General Dynamics, or a General Dynamics shareholder, full information regarding the number of shares sold at each separate sales price.
F2: Sale prices ranged from $381.575 to $382.56. Reporting Person will provide, upon request by the Commission staff, General Dynamics, or a General Dynamics shareholder, full information regarding the number of shares sold at each separate sales price.
F3: Sale prices ranged from $382.58 to $383.575. Reporting Person will provide, upon request by the Commission staff, General Dynamics, or a General Dynamics shareholder, full information regarding the number of shares sold at each separate sales price.
F4: Sale prices ranged from $383.62 to $384.07. Reporting Person will provide, upon request by the Commission staff, General Dynamics, or a General Dynamics shareholder, full information regarding the number of shares sold at each separate sales price.
F5: Includes share activity under General Dynamics 401(k) plan since date of Reporting Person's last ownership report.
F6: Represents shares held by a limited liability company for which the Reporting Person serves as a manager and the members of which are trusts for the benefit of the Reporting Person's children.
F7: Fifty percent became exercisable on 03/04/2022, and the remaining fifty percent became exercisable on 03/04/2023.
JPMORGAN CHASE & CO
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,761.5744 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 120.908 · Balance 13,761.5744 F1: Deferral of quarterly retainer, payable in common stock following termination of service as director. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 45 |
Reported balance
Holding disclosure · report date 2026-09-30 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 45 |
Filing footnotes · ownership attribution and instrument terms
F1: Deferral of quarterly retainer, payable in common stock following termination of service as director.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 24, 2017 Filed Feb 28, 2017 19:05 UTC | GENERAL DYNAMICS CORP GD · Entity 2916 | Exercise / conversionStock Options · Derivative | 75,000 | $0.00 Strike: $71.01 | $0.00 |
DisclosureSEC source: 0001209191-17-015159 · doc4.xml · derivative · entry 4 NOVAKOVIC PHEBE N · CIK 0001222195 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,720 Underlying: Common Stock · 75,000 shares Expires 2019-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fifty percent became exercisable on 03/07/2013 and the remaining fifty percent became exercisable on 03/07/2014. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 19:05 UTC | GENERAL DYNAMICS CORP GD · Entity 2916 | Tax withholdingCommon Stock, $1.00 par value | 52,998 | $189.59 | $10,047,890.82 |
DisclosureSEC source: 0001209191-17-015159 · doc4.xml · nonDerivative · entry 2 NOVAKOVIC PHEBE N · CIK 0001222195 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383,357.235 Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 19:05 UTC | GENERAL DYNAMICS CORP GD · Entity 2916 | Exercise / conversionCommon Stock, $1.00 par value | 75,000 | $71.01 | $5,325,750.00 |
DisclosureSEC source: 0001209191-17-015159 · doc4.xml · nonDerivative · entry 1 NOVAKOVIC PHEBE N · CIK 0001222195 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436,355.235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 20:37 UTC | GENERAL DYNAMICS CORP GD · Entity 2916 | GrantCommon Stock, $1.00 par value | 241.379 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-010423 · doc4.xml · nonDerivative · entry 1 NOVAKOVIC PHEBE N · CIK 0001222195 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,355.235 F1 · shares: Represents accrued dividend equivalents on previously earned PRSUs. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 19:28 UTC | GENERAL DYNAMICS CORP GD · Entity 2916 | Tax withholdingCommon Stock, $1.00 par value | 56,490 | $175.49 | $9,913,430.10 |
DisclosureSEC source: 0001209191-17-001845 · doc4.xml · nonDerivative · entry 1 NOVAKOVIC PHEBE N · CIK 0001222195 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,113.856 F1 · kind: Withholding of shares of Common Stock under General Dynamics Corporation equity compensation plan to satisfy tax withholding obligations on release of restricted shares and performance restricted stock units. Read SEC document |
| November 10, 2016 Filed Nov 15, 2016 21:02 UTC | GENERAL DYNAMICS CORP GD · Entity 2916 | GrantCommon Stock, $1.00 par value | 591.558 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-150135 · doc4.xml · nonDerivative · entry 1 NOVAKOVIC PHEBE N · CIK 0001222195 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417,604.326 F1 · shares: Represents accrued dividend equivalents on previously earned PRSUs. Read SEC document |
| April 29, 2016 Filed May 3, 2016 21:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 14,184 | $0.00 Strike: $39.48 | $0.00 |
DisclosureSEC source: 0001179110-16-023678 · edgar.xml · derivative · entry 2 NOVAKOVIC PHEBE N · CIK 0001222195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,184 Underlying: Common shares · 14,184 shares Expires 2026-04-28 F2 · security: Stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 29, 2016 Filed May 3, 2016 21:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 3,799 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-023678 · edgar.xml · nonDerivative · entry 1 NOVAKOVIC PHEBE N · CIK 0001222195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,710 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 24, 2015 Filed Apr 28, 2015 21:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 11,423 | $0.00 Strike: $48.32 | $0.00 |
DisclosureSEC source: 0001179110-15-006744 · edgar.xml · derivative · entry 2 NOVAKOVIC PHEBE N · CIK 0001222195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,423 Underlying: Common shares · 11,423 shares Expires 2025-04-23 F2 · security: Stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 24, 2015 Filed Apr 28, 2015 21:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 2,793 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-006744 · edgar.xml · nonDerivative · entry 1 NOVAKOVIC PHEBE N · CIK 0001222195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,911 F1 · kind: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 25, 2014 Filed Apr 29, 2014 21:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 14,457 | $0.00 Strike: $38.18 | $0.00 |
DisclosureSEC source: 0001179110-14-007325 · edgar.xml · derivative · entry 2 NOVAKOVIC PHEBE N · CIK 0001222195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,457 Underlying: Common shares · 14,457 shares Expires 2024-04-24 F2 · security: Stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 25, 2014 Filed Apr 29, 2014 21:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 3,535 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-007325 · edgar.xml · nonDerivative · entry 1 NOVAKOVIC PHEBE N · CIK 0001222195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,118 F1 · kind: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 26, 2013 Filed Apr 30, 2013 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 11,348 | $0.00 Strike: $36.48 | $0.00 |
DisclosureSEC source: 0001179110-13-007413 · edgar.xml · derivative · entry 2 NOVAKOVIC PHEBE N · CIK 0001222195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,348 Underlying: Common shares · 11,348 shares Expires 2023-04-25 F2 · security: Stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 26, 2013 Filed Apr 30, 2013 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 3,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-007413 · edgar.xml · nonDerivative · entry 1 NOVAKOVIC PHEBE N · CIK 0001222195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,583 F1 · kind: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 27, 2012 Filed May 1, 2012 21:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 3,333 | $0.00 Strike: $62.10 | $0.00 |
DisclosureSEC source: 0001179110-12-007449 · edgar.xml · derivative · entry 2 NOVAKOVIC PHEBE N · CIK 0001222195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Underlying: Common shares · 3,333 shares Expires 2022-04-26 F2 · security: Stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 27, 2012 Filed May 1, 2012 21:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,819 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-007449 · edgar.xml · nonDerivative · entry 1 NOVAKOVIC PHEBE N · CIK 0001222195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,486 F1 · kind: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 29, 2011 Filed May 3, 2011 21:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 3,739 | $0.00 Strike: $52.14 | $0.00 |
DisclosureSEC source: 0001179110-11-007249 · edgar.xml · derivative · entry 2 NOVAKOVIC PHEBE N · CIK 0001222195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,739 Underlying: Common shares · 3,739 shares Expires 2021-04-28 F2 · security: Stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 29, 2011 Filed May 3, 2011 21:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 2,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-11-007249 · edgar.xml · nonDerivative · entry 1 NOVAKOVIC PHEBE N · CIK 0001222195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,667 F1 · kind: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| December 06, 2010 Filed Dec 8, 2010 22:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 500 | $46.85 | $23,424.75 |
DisclosureSEC source: 0001179110-10-017178 · edgar.xml · nonDerivative · entry 1 NOVAKOVIC PHEBE N · CIK 0001222195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.